Publications

A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial

A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial
Lansky A.J., Schofer J., Tchetche D., Stella P., Pietras C.G, Parise H., Abrams K., Forrest J.K., Cleman M., Reinöhl J., Cuisset T., Blackman D., Bolotin G., Spitzer S., Kappert U., Gilard M., Modine T., Hildick-Smith D., Haude M., Margolis P., Brickman A.M., Voros S., Baumbach A. Eur Heart J. 2015 May 19. pii: ehv191. [Epub ahead of print]
The TriGuard Cerebral Protection Device is not commercially available in the USA.